Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 8, 1998, Pages 707-715

  Kruis, W ^a   Brandes, J W ^b   Schreiber, S ^c   Theuer, D ^d   Krakamp, B ^e   Schutz E ^f   Otto, P ^b   Lorenz Mayer, H ^g   Ewe, K ^h   Judmaier, G ^a  

^a Evangelisches Krankenhaus Kalk   (Germany)

^b KLINIKUM BRAUNSCHWEIG   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Städtisches Krankenhaus Merheim ^*

^e Castra Regina Center   (Germany)

^f Krankenhaus Burgwedel   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; OLSALAZINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOSCOPY; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 7344238541     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00360.x     Document Type: Article

References (20)

1. Allgayer H. Sulfasalzine and 5-ASA compounds. Gastroenterol Clin North Am 1992; 21: 643-58.
2. Meyers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196-200.
3. Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of Olsalazine and Sulfasalazine in active ulcerative colitis. Scand J Gastroenterol 1988; 23(Suppl 148): 40.
4. Rao SSC, Dundas SAC, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double-blind study. Gut 1989; 30: 675-9.
5. Feurle GE, Theuer D, Velasco S, et al. Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 1989; 30: 1354-61.
6. Ewe K, Eckardt V, Kanzler G. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects. Scand J Gastroenterol 1988; 23(Suppl. 148): 70-5.
7. Hetzel DJ, Shearman DJC, Bochner F, et al. Azodisalicylat (olsalazine) in the treatment of active ulcerative colitis. A placebo controlled trial and assessment of drug disposition. J Gastroenterol Hepatol 1986; 1: 257-66.
8. Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant to sulfasalazine. Gastroenterology 1987; 93: 1255-62.
9. Selby WS, Barr GD, Ireland A, Mason CH, Jewell DP. Olsalazine in active ulcerative colitis. Br Med J 1985; 291: 1373-5.
10. Hardy JG, Healy JNC, Reynolds JR. Evaluation of an entericcoated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 273-80.
11. Rachmilewitz D on behalf of an international study group. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J 1989; 298: 82-6.
12. Blackwelder WC. 'Proving the Null Hypothesis' in Clinical Trials. Control Clin Trials 1982; 3: 345-53.
13. ICH Topic E9. Statistical principles for clinical trials, step 3, draft. 17 January 1997.
14. Courtney MG, Numnes DP, Bergin CF, et al. Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 1992; 339: 1279-81.
15. Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
16. Hanauer S, Schwartz J, Robinson M, et al. and the Pentasa® Study group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 1188-97.
17. Schröder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-9.
18. De Dombal FT, Dew MJ, Hanauer SB, et al. Towards an optimal dosage of oral 5-ASA in ulcerative colitis. Gastroenterol Int 1992; 5 (3): 155-61.
19. Sandberg-Gertzén H, Järnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 1986; 90: 1024-30.
20. Ireland A, Mason Ch, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835-7.